Why the study?
Do bioactive peptides derived from Spirulina platensis reduce blood pressure and regulate the myocardial renin-angiotensin system in spontaneously hypertensive rats?
Do bioactive peptides derived from Spirulina platensis reduce blood pressure and regulate the myocardial renin-angiotensin system in spontaneously hypertensive rats?
Bioactive peptides from Spirulina platensis exert long-term anti-hypertensive effects and favorably modulate the myocardial renin-angiotensin system in a spontaneously hypertensive rat model.
Hypothesis-generating in hypertensive rat models; leaves open translation to human hypertension therapy.
This study investigated the long-term (8 weeks) anti-hypertensive effects of 10 mg/kg tripeptides isolated from Spirulina platensis, Ile-Gln-Pro (IQP) and Val-Glu-Pro (VEP), and S. platensis hydrolysates (SH) on spontaneously hypertensive rats. The treatment period was 6 weeks, and observation continued for another 2 weeks. After treatment, weighted systolic blood pressure, weighted diastolic blood pressure, left ventricular mass index, and right ventricular mass index of groups treated with IQP, VEP, and SH were significantly lower than those of the group treated with distilled water, even when the treatments had been withdrawn for 2 weeks. Quantitative real-time polymerase chain reaction, enzyme-linked immunosorbent assay, and Western blotting showed the mRNA expression levels and protein/peptide concentrations of the main components of the renin angiotensin system in myocardium were significantly affected by treatment: angiotensin converting enzyme, angiotensin II, and angiotensin type 1 receptor were down-regulated, whereas angiotensin type 2 receptor, angiotensin converting enzyme 2, angiotensin-(1-7), and Mas receptor were up-regulated.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: